Novo Nordisk Taps Anthropic’s Claude AI to Accelerate Drug Discovery

• Novo Nordisk teams with Anthropic to implement Claude AI models in pharmaceutical R&D
• Partnership aims for faster drug discovery, enhanced biological reasoning, and custom tool innovation

On September 16, 2026, CoinDesk reported that Novo Nordisk entered a strategic partnership with Anthropic to deploy Claude AI, including the Claude Science model, in its drug discovery and development pipelines. The collaboration is designed to streamline research timelines, strengthen biological reasoning capabilities, and jointly build custom tools targeting specific pharmaceutical obstacles.

Novo Nordisk will begin integrating Anthropic’s AI models into select research and development workflows, starting with drug discovery processes. The models are expected to address bottlenecks in pharmaceutical R&D and support biological insight. Anthropic’s technology will also extend to software engineering applications within Novo Nordisk.

Immediate impacts include faster identification of drug candidates and improved R&D efficiency, particularly in high-growth therapeutic areas like obesity and diabetes. The partnership reinforces Novo Nordisk’s ambition to become “the world’s most AI-driven healthcare company,” while bolstering Anthropic’s presence in the pharmaceutical sector.

Novo Nordisk confirmed that robust data governance and human oversight measures will be applied throughout the collaboration to ensure compliance with ethical standards.

This move is part of a wider industry shift toward leveraging advanced artificial intelligence to enhance the development of next-generation medicines. Recent partnerships by Anthropic with Bristol-Myers Squibb, OpenAI, and Amazon Web Services further underline the growing role of AI in pharma innovation.